Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses cancer cell invasion

Yong Teng, Abdulaziz Bahassan, Dayong Dong, Laura E. Hanold, Xiaoou Ren, Eileen J. Kennedy, John K. Cowell

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Activation of the WASF3 protein by extracellular stimuli promotes actin cytoskeleton reorganization and facilitates cancer cell invasion, whereasWASF3 depletion suppresses invasion and metastasis. In quiescent cells, the interaction between WASF3 and a complex of proteins, including CYFIP1, acts as a conformational restraint to prevent WASF3 activation. Therefore, we took advantage of this endogenous regulatory mechanism to investigate potential sites that disrupt WASF3 function. Here, we show that genetic knockdown of CYFIP1 in cancer cells led to the destabilization of the WASF3 complex, loss of WASF3 function, and suppressed invasion. Based on existing crystallographic data, we developed stapled peptides, referred to as WASF Helix Mimics (WAHM), that target an a-helical interface between WASF3 and CYFIP1. Treatment of highly invasive breast and prostate cancer cells with WAHM inhibitor peptides significantly reduced motility and invasion in vitro. Mechanistic investigations revealed that these inhibitors suppressed the interaction between Rac and the WASF3 complex, which has been shown to promote cell migration. Furthermore, peptide-mediated inhibition of WASF3 also resulted in the dysregulation of known downstream targets such as MMP-9 and KISS1. Finally, we demonstrate that this invasive phenotype is specific to WASF3 as depletion of WASF1 and WASF2, which can also bind to CYFIP1, did not affect invasion. Collectively, our findings suggest that targeting WASF3 function with WAHM peptides could represent a promising therapeutic strategy for preventing tumor invasion and metastasis.

Original languageEnglish (US)
Pages (from-to)965-973
Number of pages9
JournalCancer Research
Volume76
Issue number4
DOIs
StatePublished - Feb 15 2016

Fingerprint

Peptides
Neoplasms
Wiskott-Aldrich Syndrome Protein Family
Neoplasm Metastasis
Matrix Metalloproteinases
Actin Cytoskeleton
Cell Communication
Cell Movement
Prostatic Neoplasms
Breast Neoplasms
Phenotype
Proteins
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses cancer cell invasion. / Teng, Yong; Bahassan, Abdulaziz; Dong, Dayong; Hanold, Laura E.; Ren, Xiaoou; Kennedy, Eileen J.; Cowell, John K.

In: Cancer Research, Vol. 76, No. 4, 15.02.2016, p. 965-973.

Research output: Contribution to journalArticle

Teng, Yong ; Bahassan, Abdulaziz ; Dong, Dayong ; Hanold, Laura E. ; Ren, Xiaoou ; Kennedy, Eileen J. ; Cowell, John K. / Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses cancer cell invasion. In: Cancer Research. 2016 ; Vol. 76, No. 4. pp. 965-973.
@article{ce9b1830a2aa48fe887923bc1a08826f,
title = "Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses cancer cell invasion",
abstract = "Activation of the WASF3 protein by extracellular stimuli promotes actin cytoskeleton reorganization and facilitates cancer cell invasion, whereasWASF3 depletion suppresses invasion and metastasis. In quiescent cells, the interaction between WASF3 and a complex of proteins, including CYFIP1, acts as a conformational restraint to prevent WASF3 activation. Therefore, we took advantage of this endogenous regulatory mechanism to investigate potential sites that disrupt WASF3 function. Here, we show that genetic knockdown of CYFIP1 in cancer cells led to the destabilization of the WASF3 complex, loss of WASF3 function, and suppressed invasion. Based on existing crystallographic data, we developed stapled peptides, referred to as WASF Helix Mimics (WAHM), that target an a-helical interface between WASF3 and CYFIP1. Treatment of highly invasive breast and prostate cancer cells with WAHM inhibitor peptides significantly reduced motility and invasion in vitro. Mechanistic investigations revealed that these inhibitors suppressed the interaction between Rac and the WASF3 complex, which has been shown to promote cell migration. Furthermore, peptide-mediated inhibition of WASF3 also resulted in the dysregulation of known downstream targets such as MMP-9 and KISS1. Finally, we demonstrate that this invasive phenotype is specific to WASF3 as depletion of WASF1 and WASF2, which can also bind to CYFIP1, did not affect invasion. Collectively, our findings suggest that targeting WASF3 function with WAHM peptides could represent a promising therapeutic strategy for preventing tumor invasion and metastasis.",
author = "Yong Teng and Abdulaziz Bahassan and Dayong Dong and Hanold, {Laura E.} and Xiaoou Ren and Kennedy, {Eileen J.} and Cowell, {John K.}",
year = "2016",
month = "2",
day = "15",
doi = "10.1158/0008-5472.CAN-15-1680",
language = "English (US)",
volume = "76",
pages = "965--973",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses cancer cell invasion

AU - Teng, Yong

AU - Bahassan, Abdulaziz

AU - Dong, Dayong

AU - Hanold, Laura E.

AU - Ren, Xiaoou

AU - Kennedy, Eileen J.

AU - Cowell, John K.

PY - 2016/2/15

Y1 - 2016/2/15

N2 - Activation of the WASF3 protein by extracellular stimuli promotes actin cytoskeleton reorganization and facilitates cancer cell invasion, whereasWASF3 depletion suppresses invasion and metastasis. In quiescent cells, the interaction between WASF3 and a complex of proteins, including CYFIP1, acts as a conformational restraint to prevent WASF3 activation. Therefore, we took advantage of this endogenous regulatory mechanism to investigate potential sites that disrupt WASF3 function. Here, we show that genetic knockdown of CYFIP1 in cancer cells led to the destabilization of the WASF3 complex, loss of WASF3 function, and suppressed invasion. Based on existing crystallographic data, we developed stapled peptides, referred to as WASF Helix Mimics (WAHM), that target an a-helical interface between WASF3 and CYFIP1. Treatment of highly invasive breast and prostate cancer cells with WAHM inhibitor peptides significantly reduced motility and invasion in vitro. Mechanistic investigations revealed that these inhibitors suppressed the interaction between Rac and the WASF3 complex, which has been shown to promote cell migration. Furthermore, peptide-mediated inhibition of WASF3 also resulted in the dysregulation of known downstream targets such as MMP-9 and KISS1. Finally, we demonstrate that this invasive phenotype is specific to WASF3 as depletion of WASF1 and WASF2, which can also bind to CYFIP1, did not affect invasion. Collectively, our findings suggest that targeting WASF3 function with WAHM peptides could represent a promising therapeutic strategy for preventing tumor invasion and metastasis.

AB - Activation of the WASF3 protein by extracellular stimuli promotes actin cytoskeleton reorganization and facilitates cancer cell invasion, whereasWASF3 depletion suppresses invasion and metastasis. In quiescent cells, the interaction between WASF3 and a complex of proteins, including CYFIP1, acts as a conformational restraint to prevent WASF3 activation. Therefore, we took advantage of this endogenous regulatory mechanism to investigate potential sites that disrupt WASF3 function. Here, we show that genetic knockdown of CYFIP1 in cancer cells led to the destabilization of the WASF3 complex, loss of WASF3 function, and suppressed invasion. Based on existing crystallographic data, we developed stapled peptides, referred to as WASF Helix Mimics (WAHM), that target an a-helical interface between WASF3 and CYFIP1. Treatment of highly invasive breast and prostate cancer cells with WAHM inhibitor peptides significantly reduced motility and invasion in vitro. Mechanistic investigations revealed that these inhibitors suppressed the interaction between Rac and the WASF3 complex, which has been shown to promote cell migration. Furthermore, peptide-mediated inhibition of WASF3 also resulted in the dysregulation of known downstream targets such as MMP-9 and KISS1. Finally, we demonstrate that this invasive phenotype is specific to WASF3 as depletion of WASF1 and WASF2, which can also bind to CYFIP1, did not affect invasion. Collectively, our findings suggest that targeting WASF3 function with WAHM peptides could represent a promising therapeutic strategy for preventing tumor invasion and metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84960469379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960469379&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-1680

DO - 10.1158/0008-5472.CAN-15-1680

M3 - Article

C2 - 26676744

AN - SCOPUS:84960469379

VL - 76

SP - 965

EP - 973

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -